Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ana Ferreira
Observed name:
Ana M Ferreira
Institution:
Institute of Cancer Research
Observed institutions:
Royal Marsden NHS Foundation Trust,
University of Lisbon,
Institute of Cancer Research,
Royal Marsden Hospital,
Instituto de Medicina Molecular João Lobo Antunes,
University of Birmingham
show all 6
ORCID:
0000-0002-7844-2760
Observed ORCID:
0000-0002-7844-2760
OpenAlex ID:
A5065661964
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
2020
·
Lennard Y W Lee
, Jean-Baptiste Cazier
, et al.
·
The Lancet Oncology
·
629
PDF
Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19
2022
·
Csilla Várnai
, Claire Palles
, et al.
·
JAMA Network Open
·
69
PDF
Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)
2023
·
Alistair Ring
, Lucy S. Kilburn
, et al.
·
Clinical Cancer Research
·
53
PDF
BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity
2024
·
Daniel Westaby
, Juan M. Jiménez-Vacas
, et al.
·
Journal of Clinical Investigation
·
30
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial
2024
·
Pasquale Rescigno
, Nuria Porta
, et al.
·
European Journal of Cancer
·
28
PDF
SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
2022
·
Marta J. Llorca-Cardenosa
, Lauren I. Aronson
, et al.
·
Cancer Research
·
20
NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
2025
·
Jonathan Welti
, Denisa Bogdan
, et al.
·
Clinical Cancer Research
·
12
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer
2025
·
Juan M. Jiménez-Vacas
, Daniel Westaby
, et al.
·
Nature Communications
·
10
PDF
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes
2025
·
Pasquale Rescigno
, Maria Dolores Fenor de la Maza
, et al.
·
European Urology Oncology
·
5
PDF
Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
·
Clinical Cancer Research
·
3
Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
2024
·
Antje Neeb
, Ines Figueiredo
, et al.
·
Molecular Cancer Therapeutics
·
2
PDF
Abstract 3415: The neutrophil-to-lymphocyte ratio (NLR) reflects intratumor myeloid derived suppressor cell (MDSC) infiltration in metastatic castration-resistant prostate cancers (mCRPC)
2022
·
Christina Guo
, Jan Rekowski
, et al.
·
Cancer Research
·
1
Supplementary Figure 3 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Supplementary Table 4 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Data from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Supplementary Table 3 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Supplementary Table 5 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Supplemental Tables 1-2 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Supplementary Figure 4. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Supplementary Figure 5. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Supplementary Figure 1-2. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Supplementary Figure 10 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
2026
·
Antje Neeb
, Ines Figueiredo
, et al.
Supplementary Figure 8 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
2026
·
Antje Neeb
, Ines Figueiredo
, et al.
Supplementary Table 2 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
2026
·
Antje Neeb
, Ines Figueiredo
, et al.
Supplementary Figure 5 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
2026
·
Antje Neeb
, Ines Figueiredo
, et al.
Show more works
View as search
Works count:
125
Citation count:
862
H-index:
8
I10-index:
8
Year
Topic
Type